| Dr Vivek Dantapally Reddy, MBBS | |
|
30 Prospect Ave, Hackensack, NJ 07601-1915 | |
| (551) 996-4466 | |
| (551) 996-0969 |
| Full Name | Dr Vivek Dantapally Reddy |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 30 Prospect Ave, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154775294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA10848200 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Overlook Medical Center | Summit, NJ | Hospital |
| Hackensack Meridian Health Pascack Valley Medical | Westwood, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Flat, non-polypoid colorectal neoplasms (NP-CRNs), which may be difficult to detect, appear to be relatively common and may have a greater association with cancer compared with the more routinely diagnosed type of colorectal polyps, according to a study in the March 5 issue of JAMA.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Thomas Rosch, a Republican member of the U.S. Federal Trade Commission, urged the Obama administration to clarify a centerpiece of the new health care law that raises antitrust issues.
Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others
› Verified 2 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Flat, non-polypoid colorectal neoplasms (NP-CRNs), which may be difficult to detect, appear to be relatively common and may have a greater association with cancer compared with the more routinely diagnosed type of colorectal polyps, according to a study in the March 5 issue of JAMA.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Thomas Rosch, a Republican member of the U.S. Federal Trade Commission, urged the Obama administration to clarify a centerpiece of the new health care law that raises antitrust issues.
Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others
› Verified 2 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
Flat, non-polypoid colorectal neoplasms (NP-CRNs), which may be difficult to detect, appear to be relatively common and may have a greater association with cancer compared with the more routinely diagnosed type of colorectal polyps, according to a study in the March 5 issue of JAMA.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Thomas Rosch, a Republican member of the U.S. Federal Trade Commission, urged the Obama administration to clarify a centerpiece of the new health care law that raises antitrust issues.
Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vivek Dantapally Reddy, MBBS Po Box 416457, Boston, MA 02241-6457 Ph: (844) 362-1735 | Dr Vivek Dantapally Reddy, MBBS 30 Prospect Ave, Hackensack, NJ 07601-1915 Ph: (551) 996-4466 |
News Archive
Flat, non-polypoid colorectal neoplasms (NP-CRNs), which may be difficult to detect, appear to be relatively common and may have a greater association with cancer compared with the more routinely diagnosed type of colorectal polyps, according to a study in the March 5 issue of JAMA.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Thomas Rosch, a Republican member of the U.S. Federal Trade Commission, urged the Obama administration to clarify a centerpiece of the new health care law that raises antitrust issues.
Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others
› Verified 2 days ago
Dr. Sean Shabbir Sadikot, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 707, Hackensack, NJ 07601 Phone: 551-996-2211 Fax: 551-996-5727 | |
Mr. Angel J Mulkay, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 493 Essex Avenue, Hackensack, NJ 07601 Phone: 201-996-9244 Fax: 201-601-0995 | |
Dr. Morris Samuel Friedman, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 52 1st St, Hackensack, NJ 07601 Phone: 201-342-0066 Fax: 201-342-0079 | |
Dr. David Serur, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 406, Hackensack, NJ 07601 Phone: 551-996-2608 Fax: 551-996-0826 | |
Jerome F Levine, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 20 Prospect Ave, Suite 507, Hackensack, NJ 07601 Phone: 201-487-4088 | |
Dr. Noa Biran, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 2nd St, Hackensack, NJ 07601 Phone: 551-996-8704 Fax: 551-996-0582 | |
Naresh Chanderi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 344 Prospect Ave, Hackensack, NJ 07601 Phone: 201-342-4233 Fax: 201-342-4840 |